Preferred Label : Teverelix Trifluoroacetate;
NCIt synonyms : Teverelix TFA; d-Alaninamide, N-acetyl-3-(2-naphthalenyl)-d-alanyl-4-chloro-d-phenylalanyl-3-(3-pyridinyl)-d-alanyl-l-seryl-l-tyrosyl-N6-(aminocarbonyl)-d-lysyl-l-leucyl-n6-(1-methylethyl)-l-lysyl-l-prolyl-,
Bis(trifluoroacetate) (Salt);
NCIt definition : The trifluoroacetate (TFA) salt form of teverelix, a synthetic decapeptide and antagonist
of the naturally occurring gonadotropin-releasing hormone (GnRH), with potential hormone
production inhibitory and antineoplastic activities. Upon administration, teverelix
directly competes with GnRH for receptor binding in the anterior pituitary gland,
thereby inhibiting GnRH receptor signaling. This inhibits the secretion and release
of luteinizing hormone (LH) and follicle stimulating hormone (FSH). In males, the
inhibition of LH secretion prevents the release of testosterone. Since testosterone
is required to sustain prostate growth, reducing testosterone levels may inhibit hormone-dependent
prostate cancer cell proliferation. In females, this prevents the production of estrogen
by the ovaries and may relieve symptoms from sex-hormone dependent diseases.;
UNII : J5OUL9SHW5;
CAS number : 244792-29-8;
NCI Metathesaurus CUI : CL1662475;
Origin ID : C179714;
UMLS CUI : C5557582;
Semantic type(s)
- concept_is_in_subset
- has_target
